Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors
AssigneeThe Trustees of the University of Pennsylvania
InventorsShelley L. Berger, Xianxin Hua, Morgan Sammons, Jiajun Zhu
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating and preventing cancer. The invention comprises an inhibitor of epigenetic regulators, including MLL1, MLL2, MOZ, menin, WDR5, or a combination thereof. In one embodiment, the invention provides a personalized method of treating a cancer as dependent upon its epigenetic signature.
Claims14
A method of treating cancer caused by a p53 gain of function (GOF) mutation selected from the group consisting of R248Q, R248W, R249S, and R273H in a subject comprising administering to the subject an effective amount of a composition comprising at least one compound selected from the group consisting of MI-2-2 or a derivative or analogue thereof, OICR-9429 or a derivative or analogue thereof, or —N,N′-bis(4-aminophenyl)-N,N′-dimethylethylenediamine (ISC-30) or a derivative or analogue thereof:
A personalized method of treating cancer in a subject comprising detecting a p53 gain of function (GOF) mutation selected from the group consisting of R248Q, R248W, R249S, and R273H, in a tumor cell of the subject, and administering to the subject an effective amount of a composition comprising at least one compound selected from the group consisting of MI-2-2 or a derivative or analogue thereof, OICR-9429 or a derivative or analogue thereof, or —N,N′-bis(4-aminophenyl)-N,N′-dimethylethylenediamine (ISC-30) or a derivative or analogue thereof:
Dependencies are inferred from the claim text.